A randomized phase II study of CEOP with or without semustine as induction chemotherapy in patients with stage IE/IIE extranodal NK/T-cell lymphoma, nasal type in the upper aerodigestive tract

Radiotherapy and Oncology

Volumn 93, Issue 3, 2009, Pages 492-497

  Ma, Xuejun ^a   Guo, Ye ^a   Pang, Ziqiang ^a   Wang, Biyun ^a   Lu, Hongfen ^a   Gu, Ya Jia ^b   Guo, Xiaomao ^a  

^a Department of Radiation Oncology ^*

^b FUDAN UNIVERSITY   (China)

Author keywords

Chemotherapy; NK T cell lymphoma; Semustine

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; PREDNISONE; SEMUSTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; T CELL LYMPHOMA; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; HUMANS; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NOSE NEOPLASMS; PHARYNGEAL NEOPLASMS; PREDNISONE; PROGNOSIS; RADIATION INJURIES; SEMUSTINE; SURVIVAL RATE; VINCRISTINE; YOUNG ADULT;

EID: 70449635880     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.08.045     Document Type: Article

References (37)

1. Chan JKC J.E., and Ralfkiaer E. Extranodal NK/T-cell lymphoma, nasal type. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. (2001), IARC Press, Lyon, France 204-207
2. Ko Y.H., Kim C.W., Park C.S., et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer 83 (1998) 806-812
3. Au W.Y., Ma S.Y., Chim C.S., et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol 16 (2005) 206-214
4. Kim T.M., Lee S.Y., Jeon Y.K., et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol 19 (2008) 1477-1484
5. Lee J., Park Y.H., Kim W.S., et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer 41 (2005) 1402-1408
6. Chim C.S., Ma S.Y., Au W.Y., et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 103 (2004) 216-221
7. Miller T.P., Dahlberg S., Cassady J.R., et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339 (1998) 21-26
8. Reyes F., Lepage E., Ganem G., et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 352 (2005) 1197-1205
9. Li Y.X., Yao B., Jin J., et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 24 (2006) 181-189
10. Cheung M.M., Chan J.K., Lau W.H., Ngan R.K., and Foo W.W. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 54 (2002) 182-190
11. Fisher R.I., Gaynor E.R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328 (1993) 1002-1006
12. Messori A., Vaiani M., Trippoli S., Rigacci L., Jerkeman M., and Longo G. Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer 84 (2001) 303-307
13. Huang M.J., Jiang Y., Liu W.P., et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys 70 (2008) 166-174
14. Kim W.S., Song S.Y., Ahn Y.C., et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma?. Ann Oncol 12 (2001) 349-352
15. Lee J., Kim W.S., Park Y.H., et al. Nasal-type NK/T cell lymphoma: clinical features and treatment outcome. Br J Cancer 92 (2005) 1226-1230
16. Stolinsky D.C., Solomon J., Weiner J.M., and Bateman J.R. Results with CCNU in resistant Hodgkin's and non-Hodgkin's lymphoma. Oncology 33 (1976) 271-273
17. Maurice P., Glidewell O., Jacquillat C., et al. Comparison of methyl-CCNU and CCNU in patients with advanced forms of Hodgkin's disease, lymphosarcoma nad reticulum cell sarcoma. Cancer 41 (1978) 1658-1663
18. Sweetenham J.W., McKendrick J.J., Mead G.M., and Whitehouse J.M. Prednisolone, cytosine arabinoside, lomustine (CCNU), etoposide and thioguanine (PACET) combination chemotherapy for relapsed or refractory non-Hodgkin lymphoma. Eur J Cancer 29A (1993) 190-192
19. Musolino A., Perrone M.A., Michiara M., et al. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma. Cancer 103 (2005) 2109-2117
20. Guo Y., Lu J.J., Ma X., et al. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy. Oral Oncol 44 (2008) 23-30
21. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored international working group. J Clin Oncol 17 (1999) 1244
22. Kim T.M., Park Y.H., Lee S.Y., et al. Local tumor invasiveness is more predictive of survival than international prognostic index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood 106 (2005) 3785-3790
23. Horning S.J., Weller E., Kim K., et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22 (2004) 3032-3038
24. Arceci R.J. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81 (1993) 2215-2222
25. Kobayashi Y., Yamashiro T., Nagatake H., et al. Expression and function of multidrug resistance P-glycoprotein in a cultured natural killer cell-rich population revealed by MRK16 monoclonal antibody and AHC-52. Biochem Pharmacol 48 (1994) 1641-1646
26. Drenou B., Lamy T., Amiot L., et al. CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. Blood 89 (1997) 2966-2974
27. Egashira M., Kawamata N., Sugimoto K., Kaneko T., and Oshimi K. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 93 (1999) 599-606
28. Yamaguchi M., Kita K., Miwa H., et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 76 (1995) 2351-2356
29. Jung C.K., Lee K.Y., Kim Y., et al. Epstein-Barr virus infection, drug resistance and prognosis in Korean T- and NK-cell lymphomas. Pathol Int 51 (2001) 355-3563
30. Kim G.E., Yang W.I., Lee S.W., et al. Lack of correlation between P-glycoprotein and chemotherapy resistance in nasal NK/T-cell lymphomas. Leuk Lymphoma 45 (2004) 1857-1864
31. Wang B., Li X.Q., Ma X., Hong X., Lu H., and Guo Y. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am J Hematol 83 (2008) 795-799
32. Lee K.W., Yun T., Kim D.W., et al. First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leuk Lymphoma 47 (2006) 1274-1282
33. Shenkier T.N., Voss N., Fairey R., et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 20 (2002) 197-1204
34. Shikama N., Izuno I., Oguchi M., et al. Clinical stage IE primary lymphoma of the nasal cavity: radiation therapy and chemotherapy. Radiology 204 (1997) 467-470
35. Koom W.S., Chung E.J., Yang W.I., et al. Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys 59 (2004) 1127-1137
36. Li C.C., Tien H.F., Tang J.L., et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer 100 (2004) 366-375
37. Isobe K., Uno T., Tamaru J., et al. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer 106 (2006) 609-615